P1.07-009 Outcomes of Patients with Relapsed Small-Cell Lung Cancer Treated with Paclitaxel plus Gemcitabine. 10 Year-Analysis

Abstract

We conducted a retrospective study to investigate the outcome and prognostic factors of patients with relapsed SCLC who receive second or third line chemotherapy with paclitaxel plus gemcitabine, a regimen that is used in our institution since a phase II trial in 2001. We reviewed the medical records of patients with SCLC who received paclitaxel plus gemcitabine in a ten-year period, since 2005 from 2015. Overall survival (OS) from the initiation of this regimen was evaluated, plus characteristics of these patients. Patients diagnosed of SCLC were selected from our lung cancer database, and compared with our Pharmacy Department database. We selected all patients with relapsed SCLC that received therapy with paclitaxel plus gemcitabine (PG) at any moment of the disease. The median age of the cohort was 58 years (43–81 years). There were 69 males (83.2%) and 14 females (16.8%). 72 patients (86.7%) had a previous history of smoking. ECOG PS at relapse was 0 in 3 (3.6%), 1 in 70 (84.3%), and 2 in 10 (12.1%) patients. Fifty patients (60.2%) had extensive disease at baseline diagnosis, and the remaining 33 (38.8%) had limited disease. All patients were exposed previously to etoposide and platinum. The platinum used was cisplatin in 52 patients (60.3%) and carboplatin in 30 patients (38.7%). Previous radiation at local tumor site was received by 38 patients (45.8%). The response was evaluated in 78 patients. The response post-2 months of PG was complete response in 2 patients (2.5%), partial response in 29 (37.1%), stable disease in 24 (30.7%), and progressive disease in 23 patients (30.6%). The median number of cycles of PG received was 8 (2-28) cycles. Toxicity related cessation of treatment was required in 12 patients (14.4%). The reason for stoppage was Grade 3–4 toxicities in 8 patients (9.6%) and deterioration in PS in 4 patients (4.8%) The median PFS was 148 days (95% CI: 30–173.5 days) while the median OS was 172 days (95% CI: 60–485 days). Paclitaxel plus gemcitabine it is a well-tolerated regimen in relapsed SCLC in the schedule we usually use (every 2 weeks). Unless this study is retrospective, we believe that this combination can be used nowadays in these patients, if there is no clinical trial available.